|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01801 INNOVENT BIO
Nominal 
93.700 -2.550 (-2.649%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 5,953,094 | 50.624% | 9,421,888 | 6,206,070 | 4,556,380 | 4,269,729 |
| Cost of Sales | (833,452) | 23.009% | (1,510,210) | (1,136,266) | (930,990) | (505,337) |
| Gross Profit | 5,119,642 | 56.337% | 7,911,678 | 5,069,804 | 3,625,390 | 3,764,392 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (23,562) | -- | (41,009) | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 897,117 | -- | (78,621) | (1,144,411) | (2,170,469) | (2,641,717) | |
| Taxation | (62,796) | 179317.143% | (16,010) | 116,498 | (8,801) | (87,038) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 834,321 | -- | (94,631) | (1,027,913) | (2,179,270) | (2,728,755) | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (129,109) | -35.208% | (355,807) | (354,213) | (87,839) | (89,291) |
| Depreciation & Amortisation | -- | -- | 257,484 | 250,822 | 177,768 | 125,045 |
| Directors' Emoluments | -- | -- | 196,113 | 171,327 | 171,378 | 149,448 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 51.000 | -- | -6.000 | -66.000 | -146.000 | -188.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.791 | 0.095 | (1.288) | (1.391) |
| NBV per share ($) | 8.722 | -- | 8.008 | 7.724 | 6.993 | 7.065 |
| Remarks: | Real time quote last updated: 17/09/2025 12:57 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 834,321 |
| %Change | -- |
| EPS / (LPS) | RMB 0.510 |
| NBV Per Share (¥) | RMB 8.722 |